Valneva (VALN) has entered into a development and manufacturing services agreement with AGC Biologics to support phase 2 studies of an investigational four-valent Shigella bioconjugate vaccine, AGC Biologics said Tuesday.
Under the agreement, Valneva will set up phase 2 supply based on the ability of AGC's Heidelberg site to guide complex molecules through clinical stages, AGC Biologics said.
Valneva licensed the candidate from LimmaTech Biologics, which earlier worked with AGC to establish GMP-compliant manufacturing and quality control of the vaccine's complex protein-polysaccharide conjugates for first-in-human studies, according to AGC.
Financial details were not disclosed.
Price: 7.63, Change: +0.02, Percent Change: +0.29
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.